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Abstract
Background: Identification of genes responsible for medically important traits is a major challenge in human
genetics. Due to the genetic heterogeneity of hearing loss, targeted DNA capture and massively parallel
sequencing are ideal tools to address this challenge. Our subjects for genome analysis are Israeli Jewish and
Palestinian Arab families with hearing loss that varies in mode of inheritance and severity.
Results: A custom 1.46 MB design of cRNA oligonucleotides was constructed containing 246 genes responsible for
either human or mouse deafness. Paired-end libraries were prepared from 11 probands and bar-coded multiplexed
samples were sequenced to high depth of coverage. Rare single base pair and indel variants were identified by
filtering sequence reads against polymorphisms in dbSNP132 and the 1000 Genomes Project. We identified
deleterious mutations in CDH23, MYO15A, TECTA, TMC1, and WFS1. Critical mutations of the probands co-
segregated with hearing loss. Screening of additional families in a relevant population was performed. TMC1 p.
S647P proved to be a founder allele, contributing to 34% of genetic hearing loss in the Moroccan Jewish
population.
Conclusions: Critical mutations were identified in 6 of the 11 original probands and their families, leading to the
identification of causative alleles in 20 additional probands and their families. The integration of genomic analysis
into early clinical diagnosis of hearing loss will enable prediction of related phenotypes and enhance rehabilitation.
Characterization of the proteins encoded by these genes will enable an understanding of the biological
mechanisms involved in hearing loss.
Background
Clinical diagnosis is the cornerstone for treatment of
human disease. Elucidation of the genetic basis of human
disease provides crucial information for diagnostics, and
for understanding mechanisms of disease progression
and options for treatment. Hence, determination of
mutations responsible for genetically heterogeneous dis-
eases has been a major goal in genomic medicine. Deaf-
ness is such a condition, with 61 nuclear genes identified
thus far for non-syndromic sensorineural hearing impair-
ment [1] and many more for syndromes including hear-
ing loss. Despite the very rapid pace of gene discovery for
hearing loss in the past decade, its cause remains
unknown for most deaf individuals.
Most early-onset hearing loss is genetic [2]. Of genetic
cases, it is estimated that approximately 30% are syndro-
mic hearing loss, with nearly 400 forms of deafness
associated with other clinical abnormalities, and
approximately 70% are non-syndromic hearing loss,
where hearing impairment is an isolated problem [3].
Today, most genetic diagnosis for the deaf is limited to
the most common mutations in a patient’sp o p u l a t i o n
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mutations in 9 genes for hearing loss in the Israeli Jew-
ish population [4] and in 13 genes in the Palestinian
Arab population [5-7]. As elsewhere, the most common
gene involved in hearing loss in the Middle East is
GJB2, which is responsible for 27% of congenital hearing
loss among Israeli Jews [4] and 14% of congenital hear-
ing loss among Palestinian Arabs [5]. Each of the other
known genes for hearing loss is responsible for only a
small proportion of cases. The large number of these
genes, as well as in some cases their large size, has here-
tofore precluded comprehensive genetic diagnosis in
these populations. Using targeted DNA capture and
massively parallel sequencing (MPS), we screened 246
genes known to be responsible for human or mouse
deafness in 11 probands of Israeli Jewish and Palestinian
Arab origin and identified mutations associated with
hearing loss in a subset of our probands and their
extended families.
Results
Targeted capture of exons and flanking sequences of 246
genes
We developed a targeted capture pool for identifying
mutations in all known human genes and human ortho-
logues of mouse genes responsible for syndromic or
non-syndromic hearing loss. Targets were 82 human
protein-coding genes, two human microRNAs and the
human orthologues of 162 genes associated with deaf-
ness in the mouse (Additional file 1). The Agilent Sure-
Select Target Enrichment system was chosen to capture
the genomic regions harboring these genes, based on
the hybridization of complementary custom-designed
biotinylated cRNA oligonucleotides to the target DNA
library and subsequent purification of the hybrids by
streptavidin-bound magnetic bead separation [8]. The
UCSC Genome Browser hg19 coordinates of the 246
genes were submitted to the eArray website to design
120-mer biotinylated cRNA oligonucleotides that cover
all exons, both coding and untranslated regions (UTRs),
and for each exon, 40 flanking intronic nucleotides
(Additional file 2). A 3 × centered tiling design was cho-
sen and the repeat masked function was used to avoid
simple repeats [9]. A maximum 20-bp overlap into
repeats was allowed in order to capture small exons that
are closely flanked on one or both sides by short inter-
spersed elements (SINEs). Segmentally duplicated
regions were not excluded because this would preclude
identifying causative alleles in genes such as STRC [10]
and OTOA [5]. The entire design, across 246 loci,
spanned 1.59 Mb. Approximately 8% of targeted regions
failed probe design because of proximity of simple
repeats. The final capture size was 1.43 MB, including
31,702 baits used to capture 3,959 regions comprising
3,981 exons. Paired-end libraries were created from
genomic DNA samples from peripheral blood of 11 pro-
bands of families with hearing loss (Table 1) and hybri-
dized with the cRNA capture oligonucleotides.
Massively parallel sequencing of DNA libraries from
probands
The captured DNA library from each proband was
labeled with a different 6-mer barcode, and the multi-
plexed libraries (one to two libraries per lane) were ana-
lyzed with paired-end sequencing at a read length of 2 ×
72 bp, using the Illumina Genome Analyzer IIx. Across
the 1.43 MB of captured targets, median base coverage
was 757 × to 2,080 ×, with 95% and 92% of targeted
bases covered by more than 10 or 30 reads, respectively.
We aligned reads to the human reference genome
sequence (hg19) and generated SNP and indel calls for
all samples. Rare variants were identified by filtering
against dbSNP132, the 1000 Genomes project and addi-
tional filters (described in the Bioinformatics section of
Materials and methods) and classified by predicted effect
on the protein, as described in Materials and methods.
Discovery of novel mutations
In each of the 11 probands, multiple potentially func-
tional variants of predicted damaging effect were identi-
fied by our approach and validated by Sanger
sequencing (Table 1). Each validated variant was tested
for co-segregation with hearing loss in the proband’s
family. Only the variants reported below were co-inher-
ited with hearing loss.
TMC1
Family D28 is of Jewish Moroccan ancestry, now living
in Israel. Four family members with profound hearing
loss consistent with autosomal recessive inheritance
were enrolled in the study (Figure 1). In genomic DNA
from the proband D28C, two variants were observed in
the TMC1 gene, corresponding to the known mutation
c.1810C > T, p.R604X [11] and a novel variant c.1939T
> C, p.S647P (Table 2). Variant reads were 51% and
48% of total reads, suggesting heterozygosity for both
alleles. TMC1, specifically expressed in the cochlea,
encodes a transmembrane channel protein, and is a
known gene for hearing loss [12,13]. TMC1 p.S647P is
located in the sixth TMC1 transmembrane domain at a
fully conserved site and is predicted to be damaging by
PolyPhen2 and SIFT.
TMC1 p.S647P appears to be a founder mutation for
hearing loss in the Moroccan Jewish population. The
Moroccan Jewish community is an ancient population
that until recently was highly endogamous. In our
cohort, among 52 Moroccan Jewish individuals with
hearing loss, not closely related to each other by self-
report, 10 were homozygous for CX26 c.35delG, 10
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pound heterozygous for TMC1 p.S647P and p.R604X,
and 9 were heterozygous for TMC1 p.S647P. The allele
frequency of TMC1 p.S647P in this series of Moroccan
Jewish deaf is therefore (20 + 6 + 9)/104, or 0.34
(Table 3). In contrast, among 282 hearing controls of
Moroccan Jewish ancestry, 16 were heterozygous for p.
S647P and none were homozygous, yielding an allele
frequency estimate of 16/564, or 0.028, and a carrier
frequency of 5.7%. The difference between p.S647P
allele frequencies in cases and controls was significant
at P <1 0
-23. TMC1 p.S647P was not detected among
121 deaf probands or 138 hearing controls of other
Israeli Jewish ancestries.
Table 1 Numbers of rare variants detected in genomic DNA of probands with hearing loss
Rare variants Potentially functional variants
Proband Inheritance SNP Private indels Total Nonsense Missense
a Splice junctions Frameshift Total
D28C Recessive 24 14 38 0 9 0 0 9
Z686A Recessive 17 13 30 0 7 1 0 8
Z421A Recessive 20 8 28 0 6 1 1 8
K13576A Dominant 31 42 73 0 13 1 0 14
W1098A Dominant 38 8 46 0 15 2 0 17
DC5 Recessive 21 47 68 0 5 0 0 5
DQ3 Recessive 26 58 84 0 11 0 0 11
DR3 Recessive 18 60 78 1 6 1 0 8
CJ3 Recessive 19 52 71 0 3 0 0 3
CK3 Recessive 29 61 90 0 9 1 0 10
DE3 Recessive 26 53 79 1 8 1 0 10
aMissense variants predicted to be benign by PolyPhen2 and SIFT are excluded from the missense mutations listed above.
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Figure 1 Pedigrees of families with TMC1 mutations. (a) TMC1 p.R604X and p.S647P were discovered by targeted capture and MPS. TMC1 p.
R389X and p.W404R were subsequently identified in probands heterozygous for one of the first two alleles. Segregation of alleles with hearing
loss is indicated by wild-type (N) and deafness-associated variants (V). The black arrow indicates the proband in each family. (b) Sanger
sequences of each variant for representative homozygous or heterozygous individuals. The red arrow indicates the mutation.
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TMC1 in genomic DNA of the seven probands hetero-
zygous for TMC1 p.S647P revealed TMC1 c.1165C > T,
p.R389X [14] as the second pathogenic allele in two
probands. In two other probands heterozygous for
TMC1 p.S647P, the novel variant TMC1 c.1210T > C,
p.W404R, with PolyPhen2 score 0.567, was revealed as a
possible second pathogenic allele (Figure 1). Neither
TMC1 p.R389X nor TMC1 p.W404R were found in an
additional 51 Moroccan deaf probands or 82 Moroccan
Jewish controls. We estimate that TMC1 mutations
e x p l a i na tl e a s t3 8 %o fi n h e r i t e dh e a r i n gl o s si nt h e
Moroccan Jewish population.
CDH23
Family Z686 is of Jewish-Algerian descent, now living in
Israel. Nine family members with profound hearing loss
and two relatives with normal hearing enrolled in the
study (Figure 2). Hearing loss in the family is consistent
with autosomal recessive inheritance. In genomic DNA
from proband Z686A, a novel variant in CDH23 was
observed in 100% of reads, indicating homozygosity
(Table 2). This variant corresponds to CDH23 c.7903G
> T, p.V2635F and co-segregates perfectly with hearing
loss in the extended kindred (Figure 2). CDH23 p.
V2635F is predicted to be damaging by PolyPhen2 and
SIFT. The CDH23 mutation was screened in hearing
controls and deaf probands of Jewish origin (Table 3).
Proband Z438A, of Algerian origin, was homozygous for
the mutation, which segregated with hearing loss in his
family. Another deaf proband with partial Algerian
ancestry, D16C, was heterozygous for CDH23 p.V2635F.
All 68 exons of CDH23 were sequenced in genomic
DNA of D16C, but no second mutation was detected.
D16C may be a carrier of CDH23 p.V2635F, with his
hearing loss due to another gene.
MYO15A
Family Z421 is of Jewish Ashkenazi origin. Hearing loss
in the family is consistent with recessive inheritance
(Figure 2). The proband is heterozygous for two novel
variants in MYO15A (Tables 2 and 3). The first variant,
corresponding to MYO15A c.8183G > A (p.R2728H),
was supported by 50% (43/86) of reads and is predicted
to be damaging by PolyPhen2 and SIFT. The other
MYO15A variant was cryptic. It was read as two single
Table 2 Mutations identified by targeted capture and MPS in families with non-syndromic hearing loss
Proband Inheritance Genomic
coordinates
a
Reference
reads
Variant
reads
Total
reads
Gene cDNA (RefSeq ID) Protein (RefSeq
ID)
PolyPhen-2
HumVar score
D28C Recessive chr9:75435804 C
>T
643 666 1,309 TMC1 c.1810C > T
(NM_138691)
p.R604X
(NP_619636)
Nonsense
chr9:75435933 T
>C
770 707 1,477 TMC1 c.1939T > C
(NM_138691)
p.S647P
(NP_619636)
0.912
Z686A Recessive chr10:73565593
G>T
0 425 425 CDH23 c.7903G > T
(NM_022124.5)
p.V2635F
(NP_071407)
0.876
Z421A Recessive chr17:18058028
G>A
43 43 86 MYO15A c.8183G > A
(NM_016239)
p.R2728H
(NP_057323)
0.992
chr17:18022487
delCG
b
MYO15A c.373delCG
(NM_016239)
p.R125VfsX101
(NP_057323)
Frameshift
DC5 Recessive chr17:1,035800 G
>A
08 9 8 9 MYO15A c.4240G > A
(NM_016239)
p.E1414K
(NP_057323)
0.971
K13576A Dominant chr4:6304112 G
>A
86 90 176 WFS1 c.2756G > A
(NM_001145853)
p.E864K
(NP_001139325)
0.959
W1098A Dominant chr11:121038773
C>T
855 808 1,663 TECTA c.5597C > T
(NM_005422.2)
p.T1866M
(NP_005413)
0.995
ahg19.
bDetected as two SNPs by MPS (see explanation in text).
Table 3 Allele frequency among unrelated deaf and controls of the same population of origin as the proband
Allele frequency in population of origin (number of chromosomes)
Gene Mutation Origin of proband Unrelated deaf (sample size) Controls (sample size)
TMC1 p.R604X Morocco, Jewish 0.058 (6/104) 0 (0/256)
TMC1 p.S647P Morocco, Jewish 0.337 (35/104) 0.028 (16/564)
CDH23 p.V2635F Algeria, Jewish 0.192 (5/26) 0 (0/106)
MYO15A p.R2728H Ashkenazi Jewish 0.010 (3/288) 0 (0/316)
MYO15A p.R125VfsX101 Ashkenazi Jewish 0.008 (1/120) 0.006 (3/480)
MYO15A p.E1414K Palestinian Arab 0.005 (2/434) 0 (0/480)
WFS1 p.E864K Ashkenazi Jewish 0 (0/102) 0 (0/100)
TECTA p.T1866M Turkey, Jewish 0.067 (1/15) 0 (0/270)
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> G and chr17:18,022,488 G > C, but each variant was
supported by only 25% of reads. In our experience, two
apparently adjacent or nearly adjacent single base-pair
variants with similar numbers of reads, each with weak
support, may reflect an underlying insertion or deletion.
We sequenced MYO15A exon 2 containing these variant
sites and detected a 2-bp deletion MYO15A c.373delCG
(p.R125VfsX101). MYO15A p.R2728H and MYO15A
c.373delCG co-segregated with hearing loss in the
family. MYO15A, which encodes a myosin expressed in
the cochlea, harbors many mutations worldwide respon-
sible for hearing loss [15,16], but neither MYO15A p.
R2728H nor MYO15A c.373delCG has been described
previously.
Family DC is of Palestinian Arab origin. Hearing loss
in the family is congenital, profound, and recessive (Fig-
ure 2). The proband is homozygous for MYO15A
c.4240G > A (p.E1414K), a novel mutation predicted to
be damaging by Polyphen2 and SIFT (Tables 2 and 3).
WFS1
Family K13576 is of Ashkenazi Jewish origin. Hearing
loss in the family is dominant (Figure 2). Audiograms of
affected relatives reveal hearing thresholds in a U-
shaped pattern, with poorest hearing in low and middle
frequencies. The proband is heterozygous for missense
mutation WFS1 c.2765G > A (p.E864K) (Tables 2 and
3). WFS1 encodes wolframin. Homozygosity for this
mutation is known to cause Wolfram syndrome, which
includes optic atrophy and non-insulin-dependent dia-
betes mellitus (MIM ID 606201.0020) [17,18]. Hetero-
zygosity for this mutation is responsible for non-
syndromic low-frequency hearing loss in a Japanese
family [19] with a similar phenotype to that of family
K13576.
TECTA
Family W1098 is of Turkish Jewish descent. Hearing
loss in the family is dominant (Figure 2). The critical
mutation in the proband is TECTA c.5597C > T (p.
T1866M) (Tables 2 and 3), which encodes alpha-
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Figure 2 Pedigrees of families with CDH23, MYO15A, TECTA,a n dWFS1 mutations. (a) Segregation of hearing loss with wild-type (N) and
deafness-associated variants (V) in each family. (b) Sanger sequences of each variant.
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ciated with dominantly inherited hearing loss in other
families [21,22].
In addition to the probands described above, in five
other probands of Palestinian Arab origin (DR3, DE5,
DQ3, CJ3 and CK3), multiple variants were identified by
capture and sequencing, and validated by Sanger
sequencing, but none co-segregated with hearing loss in
the families (Table 1). In these families, hearing loss
could be due to mutations in non-captured regions of
genes in our pools or by as-yet-unknown genes.
Discussion
T h eg o a lo fo u rs t u d yw a st oa p p l yD N Ac a p t u r ea n d
MPS to identify inherited mutations involved in hearing
loss. We designed oligonucleotides to capture the exons
and regulatory regions of 246 genes involved in hearing
loss, in human or in mouse. The inclusion of genes thus
far known to be involved in deafness in the mouse is
based on the observation that many genes for human
deafness are responsible for mouse deafness as well
[23,24]. Among the genes harboring mutations causing
deafness only in the mouse, no deleterious mutations
were present in these 11 human families. The mouse
genes will be sequenced from DNA of many more
human families in the future.
Comprehensive targeted enrichment and MPS has
been employed previously for non-syndromic hearing
loss [25]. Our approach targeted more genes (246 versus
54), including in particular genes associated with deaf-
ness in the mouse. Our goal in including these genes is
to speed future discovery of additional human deafness
genes that are orthologues of known mouse genes.
To date, routine clinical diagnostic tests for deafness
in the Middle East have consisted of restriction enzyme
analysis of the two common GJB2 mutations, and on
occasion, DNA sequencing of the GJB2 coding region.
In some clinics, screening for the relevant mutations in
other genes on the basis of ethnic origin, audiological
tests, family history, personal history and findings from
physical examination may be performed. Comprehensive
testing for genes with mutations common in other
populations, such as TMC1 [11,26], MYO15A [15] or
SLC26A4 [27], is not available from health services in
the Middle East due to the high cost of testing these
genes by Sanger sequencing. The large size of these
genes has also precluded their analysis in Middle East-
ern research laboratories.
A major challenge for mutation discovery is determining
which variants are potentially causative and which are
likely benign. This is particularly difficult when sequencing
populations that are not well represented in dbSNP. A
novel variant may represent a previously undiscovered
common population-specific polymorphism or a truly
private mutation. Sequencing even a small number of
samples (say 100) from the same ethnic background serves
as a very effective filter. In our study, many variants not in
dbSNP were nonetheless common in our populations and
could be ruled out as causative mutations (Additional file
3). As a result, a smaller fraction of the detected variants
had to be verified by Sanger sequencing for segregation in
the family.
For the Israeli deaf population of Moroccan Jewish
ancestry, this study has substantial clinical implications,
as the TMC1 gene was found to be very frequently
involved in deafness in this population. Recessive muta-
tions in TMC1 were detected in more than a third
(38%) of hearing impaired Jews of Moroccan origin. A
single DNA sample of a Moroccan Jewish proband, eval-
uated by this approach, led to the discovery of four
mutations, two of them novel, and solved the cause of
hearing loss of an additional 20 families. The TMC1
gene is the sixth most common cause of recessive hear-
ing loss worldwide [27]. The two novel mutations in
Moroccan Jewish deaf individuals add to the 30 reces-
sive mutations that have been reported to date in the
TMC1 gene [27]. In some populations, including Iran
[26] and Turkey [11], as Israel, TMC1 is one of the
genes most frequently involved in deafness. Based on
these results, we recommend that all Israeli Jewish pro-
bands of Moroccan ancestry be screened for the four
TMC1 mutations, as well as for the most common GJB2
mutations, prior to conducting MPS. An immediate
r e s u l to ft h e s ef i n d i n g si st h a ts c r e e n i n gf o rTMC1
mutations will become routine in Israel for all hearing
impaired patients of Moroccan Jewish ancestry.
Novel mutations were identified in multiple other
genes - CDH23, MYO15A, WFS1, and TECTA -t h a ta r e
known to be responsible for hearing loss but are not
routinely evaluated, largely because of their size. Tar-
geted MPS makes it feasible to screen large genes that
have heretofore been largely untested. As sequencing
chemistry improves, we believe it will be feasible to mul-
tiplex 12 samples per lane and still maintain a high cov-
erage (> 200 ×). It will thus become even more
straightforward to screen comprehensively for all known
hearing loss genes.
Of the six Palestinian families enrolled in this study, a
causative mutation was found in only one. This result is
probably due to two factors. First, familial hearing loss
in the Palestinian population has been very thoroughly
investigated for more than a decade, with the discovery
of many critical genes and the characterization of the
mutational spectra of these genes as they were identified
(for example, [5,7,28,29]). Therefore, the mutations
responsible for hearing loss in many Palestinian families
were known before this project was undertaken. Second,
as the result of historical marriage patterns, inherited
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more heterogeneous, at the levels of both alleles and
loci, than is inherited hearing loss in the Israeli popula-
tion. A large proportion of Palestinian families are likely
to have hearing loss due to as yet unknown genes. Since
the molecular basis of deafness in most of our Palesti-
nian probands was unsolved, we predict that many new
genes for hearing loss remain to be found. These may
be optimally resolved by exome sequencing in combina-
tion with homozygosity mapping, as we previously
demonstrated [6].
Conclusions
Multiple mutations responsible for hearing loss were
identified by the combination of targeted capture and
MPS technology. Screening multiple families for alleles
first identified in one proband led to the identification
of causative alleles for deafness in a total of 25 of 163
families. The approach described here exploits the high
throughput of targeted MPS to make a single fully com-
prehensive test for all known deafness genes. Although
we applied it within the context of familial hearing loss,
the test could also be used in cases of isolated deafness.
This strategy for clinical and genetic diagnosis will
enable prediction of phenotypes and enhance rehabilita-
tion. Characterization of the proteins encoded by these
genes will enable a comprehensive understanding of the
biological mechanisms involved in the pathophysiology
of hearing loss.
Materials and methods
Family ascertainment
The study was approved by the Helsinki Committees of
Tel Aviv University, the Israel Ministry of Health, the
Human Subjects Committees of Bethlehem University,
and the Committee for Protection of Human Subjects of
the University of Washington (protocol 33486). Eleven
probands and both affected and unaffected relatives in
their families were ascertained. A medical history was
collected, including degree of hearing loss, age at onset,
evolution of hearing impairment, symmetry of the hear-
ing impairment, use of hearing aids, presence of tinni-
tus, medication, noise exposure, pathologic changes in
the ear, other relevant clinical manifestations, family his-
tory and consanguinity. The only inclusion criteria for
our study were hearing loss and family history. Blood
was drawn when subjects signed committee-approved
consent forms for DNA extraction, and genomic DNA
was extracted.
Gene exclusion
All subjects were tested for GJB2 [4] by standard Sanger
sequencing. The other eight deafness genes in the Jewish
population have low prevalence and their known
mutations were screened only in subjects manifesting a
relevant phenotype or ethnic background. These genes
include GJB6 [30], PCDH15 [31], USH1C [4], MYO3A
[32], SLC26A4 [33], POU4F3 [34], the inverted duplica-
tion of TJP2 [35], and LOXHD1 [36]. All known deaf-
ness-causing mutations in the Palestinian population
were excluded, including mutations in CDH23, MYO7A,
M Y O 1 5 A ,O T O F ,P J V K ,S L C 2 6 A 4 ,T E C T A ,T M H S ,
TMPRSS3, OTOA, PTPRQ, and GPSM2 [5-7].
Capture libraries
Exons and the flanking 40 bp into introns of 246 human
genes were selected for capture and sequencing. The
246 genes are listed in Additional file 1, and the target
sequences are listed in Additional file 2. The exons were
uploaded from both NIH (RefSeq) and UCSC databases,
using the UCSC Genome Browser. These genes have
been linked with hearing loss in humans or their ortho-
logous genes have been associated with hearing loss in
mice. We designed 3x tiling biotinylated cRNA 120-mer
oligonucleotides to capture the selected sequences for
Illumina paired-end sequencing, using the eArray algo-
rithm, and these were purchased from Agilent Technol-
ogies (SureSelect Target Enrichment System).
Paired-end libraries were prepared by shearing 3 μgo f
germline DNA to a peak size of 200 bp using a Covaris
S2. DNA was cleaned with AmpPure XP beads (which
preferentially removes fragments < 150 bp), end
repaired, A-tailed and ligated to Illumina indexing-speci-
fic paired-end adapters. The libraries were amplified for
five cycles with flanking primers (forward primer PE 1.0
and reverse primer SureSelect Indexing Pre-Capture
PCR). The purified amplified library (500 ng) was then
hybridized to the custom biotinylated cRNA oligonu-
cleotides for 24 hours at 65°C. The biotinylated cRNA-
DNA hybrids were purified with streptavidin-conjugated
magnetic beads, washed, and the cRNA probes were
digested, following cleaning of the captured DNA frag-
ments with AmpPure XP beads. Barcode sequences for
multiplex sequencing were added to the captured DNA
samples, and a post capture PCR was performed for 14
cycles. The libraries were prepared using reagents from
Illumina (Genomic DNA Sample Preparation Kit and
Multiplexing Sample Preparation Oligonucleotide Kit)
and Agilent (SureSelect Target Enrichment System Kit),
according to Agilent’s instructions. The final concentra-
tion of each captured library was determined by a Qubit
fluorometer and multiple aliquots diluted to 0.5 ng/μl
were analyzed on a high sensitivity chip with a Bioanaly-
zer 2100.
Massively parallel sequencing
Af i n a lD N Ac o n c e n t r a t i o no f1 2p Mw a su s e dt oc a r r y
out cluster amplification on v4 Illumina flow cells with
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72-bp paired-end recipe plus a third read to sequence
the 6-bp index to sequence 11 captured library samples
in total (Table 1), multiplexed in 7 lanes (1 or 2 multi-
plexed samples per lane), on the Illumina Genome Ana-
lyzer IIx, following the manufacturer’s protocol. After
running the GERALD demultiplexing script (Illumina),
approximately 8 Gb of passing filter reads were gener-
ated for samples loaded in pairs on the flow cell lanes,
and approximately 16 and approximately 19 Gb were
generated for samples CK3 and W1098 that were loaded
alone, respectively. The reads were aligned to our BED
file of bait probe (capture) targets, and reads that were
not included in the captured sequences were discarded.
The average on-target capture efficiency was 66%. The
median base coverage was 757 × to 2,080 ×. Samples
that were loaded alone on a lane had an average base
coverage of 1970 ×, while samples loaded two in lane
had an average base coverage of 937 ×. Overall, 94.7%
of our targeted bases were covered by more than 10
reads, and 92% were covered by more than 30 reads,
our cutoffs for variant detection. The remaining
approximately 5% of the poorly covered regions (< 10
reads) were in extremely high GC-rich regions. Raw
sequencing data are available at the EBI Sequence Read
Archive (SRA) with accession number ERP000823.
Bioinformatics
To identify SNPs and point mutations, data were aligned
to hg19 using Burrows-Wheeler Aligner (BWA) [37] and
MAQ [38], after removal of reads with duplicate start and
end sites. BWA was also used to calculate average cover-
age per targeted base. SNP detection was performed using
the SNP detection algorithms of MAQ and SNVmix2 [39];
the latter was also used to count the real number of var-
iant and consensus reads for each SNP, to distinguish
between heterozygote and homozygote variants. In addi-
tion, a read-depth algorithm was used to detect exonic
deletions and duplications [40]. In order to sort potentially
deleterious alleles from benign polymorphisms, perl scripts
(available from the authors by request) were used to filter
the variants (SNPs and indels) obtained against those of
dbSNP132. Because dbSNP132 includes both disease-asso-
ciated and benign alleles, known variants identified by
NCBI were included only if clinically associated. The Var-
iantClassifier algorithm [41] was used to add the following
information for surviving variants: gene name, the pre-
dicted effect on gene (at or near splice site) and protein
function (missense, nonsense, truncation), context (coding
or non-coding sequence), and if it is in coding sequence,
the amino acid change.
The Placental Mammal Basewise Conservation by
PhyloP (phyloP46wayPlacental) score for the consensus
nucleotide in each SNP was obtained from the UCSC
Genome Browser, and variants with a score < 0.9 were
considered as non-conserved and discarded from the
SNP lists. Since we sequenced DNA samples of 11 pro-
bands from similar ethnic groups, we also counted the
number of probands that carry each variant, finding
many novel variants that are common in the Jewish
and/or Palestinian ethnic groups, although not included
in dbSNP132, which are most probably non-damaging
variants. For variants of conserved nucleotides that pre-
sent in up to three probands, we also checked if this
variant was already reported in the 1000 Genomes pro-
ject or in other published genomes from hearing
humans.
The effect of rare or private non-synonymous SNPs
was assessed by the PolyPhen-2 (Prediction of functional
effects of human nsSNPs) HumVar score [42] and SIFT
algorithm (Sorting Tolerant From Intolerant) [43], which
predict damage to protein function or structure based on
amino acid conservation and structural data. Although
thousands of variants were detected in each proband
(both SNPs and indels), this analysis yielded a small num-
ber of variants that may affect protein function.
Sanger sequencing
Sequencing was performed using the ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction Kit (Per-
kin-Elmer Applied Biosystems, Foster City, CA, USA)
and an ABI 377 DNA sequencer.
Restriction enzyme assays
For screening unrelated deaf individuals and population
controls, restriction enzyme assays were designed for
detection of CDH23 c.7903G > T (p.V2635F); TMC1
c.1810C > T (p.R604X), c.1939T > C (p.S647P) and
c.1210T > C, W404R; MYO15A c.8183G > A (p.
R2728H) and c.373delCG (p.R125VfsX101); and TECTA
c.5597C > T (p.T1866M) (Additional file 4). PCR assays
were used for MYO15A c.4240G > A (p.E1414K) and
WFS1 c.2765G > A (p.E864K) (Additional file 4).
Additional material
Additional file 1: Table of human genes captured.
Additional file 2: Table of captured sequences.
Additional file 3: Tables of indels and SNPs in four or more
probands in our population. (a) Table of indels appearing in four or
more probands in our population (n = 11). (b) Table of SNPs in four or
more probands in our population (n = 11).
Additional file 4: Table of primers and restriction enzyme digestion
assays.
Abbreviations
bp: base pair; indel: insertion-deletion; MPS: massively parallel sequencing;
SNP: single nucleotide polymorphism.
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